DRIO vs. LUCD, CTSO, GBS, XAIR, NSPR, CTCX, DXR, CODX, ICU, and LNSR
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Lucid Diagnostics (LUCD), Cytosorbents (CTSO), GBS (GBS), Beyond Air (XAIR), InspireMD (NSPR), Carmell (CTCX), Daxor (DXR), Co-Diagnostics (CODX), SeaStar Medical (ICU), and LENSAR (LNSR). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
DarioHealth has a net margin of -165.96% compared to Lucid Diagnostics' net margin of -2,169.07%. DarioHealth's return on equity of -48.84% beat Lucid Diagnostics' return on equity.
DarioHealth currently has a consensus price target of $4.05, indicating a potential upside of 157.96%. Lucid Diagnostics has a consensus price target of $2.75, indicating a potential upside of 191.19%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than DarioHealth.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 10.1% of DarioHealth shares are held by company insiders. Comparatively, 4.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Lucid Diagnostics has lower revenue, but higher earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lucid Diagnostics had 4 more articles in the media than DarioHealth. MarketBeat recorded 6 mentions for Lucid Diagnostics and 2 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.93 beat Lucid Diagnostics' score of 0.15 indicating that DarioHealth is being referred to more favorably in the media.
DarioHealth received 213 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. Likewise, 67.04% of users gave DarioHealth an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
DarioHealth has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Summary
DarioHealth beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
